This study ( NCT@ ) evaluated , first , the bioequivalence ( BE ) of a fixed-dose combination ( FDC ) tablet containing dolutegravir @ mg , abacavir @ mg , and lamivudine @ mg ( dolutegravir/abacavir/lamivudine FDC ) vs coadministered dolutegravir @ mg and abacavir/lamivudine combination tablets ( Epzicom ) and , second , the effect of food on the dolutegravir/abacavir/lamivudine FDC tablet .